STD Diagnostics Market Size & Share 2024 – 2032

STD Diagnostics Market Size

STD Diagnostics Market size was valued at USD 13.8 billion in 2023 and is estimated to expand at over 7.2% CAGR from 2023 to 2032. STD diagnostics refers to the process of identifying and diagnosing sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs). STD diagnostics involve various tests and procedures aimed at detecting the presence of pathogens, such as bacteria, viruses, parasites, and fungi, that are transmitted through sexual contact. The rising incidence of sexually transmitted diseases (STDs) have become a significant public health concern globally.

For instance, the World Health Organization (WHO) reports over 1 million daily STI cases globally, with most cases being asymptomatic. Annually, about 374 million new infections of curable STIs occur. Thus, as the prevalence of sexually transmitted diseases (STDs) continues to rise globally, there is a growing need for effective management and treatment options such as STD testing and preventive measures.
 

Furthermore, public, and private organizations are significantly investing in research and development efforts to innovate and enhance various in-vitro diagnostics methods which is estimated to reach 141 billion by 2032. These investments stimulate the advancement of new and enhanced diagnostic tools for STDs, such as HIV diagnostics.
 

STD Diagnostics Market Trends

There is increasing awareness among healthcare providers and patients regarding the benefits of utilizing STD diagnostics, as it facilitates prompt treatment initiation. Through early identification of infected individuals, screening programs play a crucial role in preventing the further spread of STDs within the community.
 

• Thus, this awareness has led to greater adoption of STD diagnostics among healthcare professionals and patients alike.
   
• Furthermore, ongoing advancements in technology have resulted in the creation of more sophisticated and user-friendly devices for sexually transmitted diseases (STDs).
   
• For instance, Abbott's Alinity m STI Assay, approved by the Food and Drug Administration (FDA) in May 2022, is a multiplex test capable of simultaneously detecting and distinguishing four prevalent STDs.
   
• These technological enhancements improve the efficiency of diagnostic tests, increase patient compliance with testing protocols, and diminish the likelihood of adverse effects associated with STD treatments.
   

STD Diagnostics Market Analysis

Based on product type, the market is segmented into instruments/analyzers, and consumables. The consumables segment is projected to reach USD 18.3 billion by the end of 2032.
 

• Consumables play a vital role in the comprehensive management of STDs by facilitating accurate diagnosis, prompt treatment initiation, preventive measures, and patient education.
   
• Furthermore, consumables such as test kits, reagents, and specimen collection materials enable accurate and reliable diagnosis of STDs. This facilitates timely identification of infections, allowing for prompt initiation of treatment.
   
• Moreover, consumables designed for rapid diagnostic tests (RDTs) provide quick results, often within minutes. This rapid turnaround time enables healthcare providers to offer same-day diagnosis and treatment, improving patient outcomes and reducing the risk of disease transmission.

Learn more about the key segments shaping this market

Download Free PDF

Based on test type, the STD diagnostics market is segmented into laboratory testing and point of care (PoC) testing. The laboratory testing segment held over USD 9.5 billion revenue in 2023, holds prominence due to its accuracy, reliability, and comprehensive screening capabilities.
 

• Laboratory tests offer higher accuracy compared to point-of-care testing, making them essential for precise diagnosis and monitoring of sexually transmitted diseases (STDs).
   
• With specialized equipment, trained personnel, and standardized protocols, laboratory testing ensures quality control and adherence to regulatory standards.
   
• Moreover, laboratory facilities can process a large volume of samples efficiently, enabling timely testing and result reporting, crucial for patient management and public health surveillance.
   

Based on disease, the STD diagnostics market is segmented into CT/NG, syphilis, gonorrhea, genital herpes (HSV I & HSV II), HPV, HIV/AIDS, ureaplasma & mycoplasma, trichomoniasis, VZV, and other diseases. The syphilis segment to cross USD 7 billion revenue size by the end of 2032.
 

• Syphilis is a sexually transmitted disease (STD) caused by the bacterium treponema pallidum. It can be transmitted through sexual contact, including vaginal, anal, or oral sex, as well as through close skin-to-skin contact with an infected sore during early stages of the disease.
   
• For instance, the World Health Organization (WHO) estimated that in 2020 approximately 7.1 million adults aged 15–49 globally acquired syphilis.
   
• Furthermore, syphilis is treatable with antibiotics, especially in its early stages. Thus, prompt diagnosis and treatment can prevent the progression of the disease and reduce the risk of serious complications, such as neurosyphilis and cardiovascular syphilis.
   

Based on technology, the STD diagnostics market is segmented into immunoassay, molecular diagnostics, and other technologies. The immunoassay segment accounted for USD 6.6 billion revenue in 2023.
 

• Immunoassays are highly sensitive and specific, allowing for accurate detection of STD-related antigens or antibodies in patient samples. This ensures reliable results, minimizing false positives and false negatives.
   
• Furthermore, many immunoassays provide rapid results, enabling timely diagnosis and treatment initiation. Quick turnaround times are especially beneficial for point-of-care testing and emergency situations, allowing for prompt intervention and disease management.
   
• Moreover, immunoassays for STDs offer numerous advantages, including high sensitivity and specificity, rapid results, ease of use, automation capabilities, versatility, cost-effectiveness, non-invasive sampling, and support for screening programs.
   

Based on end-use, the STD diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, home care testing, and other end-users. The hospitals and clinics segment is poised to surpass USD 11.2 billion by the end of 2032.
 

• Hospitals and clinics play pivotal role in managing sexually transmitted diseases, as they typically employ healthcare professionals who specialize in the diagnosis, treatment, and management of STDs.
   
• Furthermore, hospitals and clinics typically offer a wide range of STD testing services, including screening, diagnostic tests, and follow-up monitoring.
   
• Moreover, hospitals and clinics provide essential services for the prevention, diagnosis, and treatment of sexually transmitted diseases, offering expertise, comprehensive testing services, confidentiality, integrated care, access to medications, preventive services, community outreach, and research opportunities to improve patient outcomes and public health.

North America STD diagnostics market size dominated around USD 5.6 billion in 2023.
 

• The large market share in the STD diagnostics sector is correlated with a sophisticated healthcare infrastructure, rising prevalence of sexually transmitted diseases such as HIV, rapid technological advancement, substantial healthcare spending, and the growing elderly population.
   
• For instance, according to the Centers for Disease Control and Prevention (CDC) in 2021 the U.S experienced approximately 32,100 new HIV infection cases.
   
• Furthermore, favorable reimbursement policies and government initiatives aimed at sexually transmitted diseases (STD) management and prevention further propel the market growth in North America.
   

STD Diagnostics Market Share

The STD diagnostics industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, Thermo Fisher Scientific, Becton, Dickinson, and Company among others have a notable presence in the market.
 

STD Diagnostics Market Companies

Some of the eminent market participants operating in the STD diagnostics industry include:

• Abbott Laboratories
• Becton, Dickinson, and Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• QIAGEN N.V.
• Seegene Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Trinity Biotech plc       

STD Diagnostics Industry News:

• In February 2023, Thermo Fisher Scientific announced the launch of its Applied Biosystems TrueMark STI select panel, a polymerase chain reaction (PCR) research used to detect neisseria gonorrhoeae, mycoplasma genitalium, chlamydia trachomatis, and trichomonas vaginalis in a single test. This launch expanded company’s portfolio of diagnostic solutions and provided a competitive edge within the market.
   
• In August 2022, Bio-Rad Laboratories, Inc. announced its acquisition of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A., a developer based in Warsaw, Poland, known for innovative technology solutions in medical diagnostics and healthcare markets. This acquisition expected to enhance the company's competitive position in the diagnostic market.
   

The STD diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Instruments/analyzers
  • Laboratory devices
    • Thermal cyclers – PCR
    • Lateral flow readers
    • Flow cytometers
    • Absorbance microplate reader
    • Differential light scattering machines
    • Other laboratory devices
  • Point of care devices
    • Phone chips (Microfludics + ICT)
    • Portable/bench top/rapid diagnostic kits 
• Consumables

Market, By Test Type

• Laboratory testing
• Point of care (PoC) testing

Market, By Disease

• Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
• Syphilis
• Gonorrhea
• Genital herpes (HSV I & HSV II)
• HPV (Human papillomavirus)
• HIV/AIDS (Human immunodeficiency virus/ acquired immunodeficiency syndrome)
• Ureaplasma & mycoplasma
• Trichomoniasis
• VZV (Varicella zoster virus)
• Other diseases

Market, By Technology

• Immunoassay
• Molecular diagnostics
• Other technologies

Market, By End-use

• Hospitals & clinics
• Diagnostic laboratories
• Home care testing
• Other end-users

The above information has been provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa